Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab
Has adequate bone marrow function; platelet count \> 100 x 10\^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC \> or = 1 x 10\^9/L, and hemoglobin \> or = 9.5 g/dL
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has adequate liver function
must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle
must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (platelet count \< 50 x 10\^9/L) as a result of the chemotherapy administered in the cycle immediately preceding study entry
has serum creatinine concentration \< or = 2 mg/dl
You may not be if
More that 1 prior relapse chemotherapy regimen
Sepsis, disseminated coagulation or any other condition that may exacerbate thrombocytopenia
Significant bleeding (CTC grade 3 or 4)
History of thromboembolic disease
Subjects who are identified by clinical history and/or serological testing to have either acute or chronic hepatitis B or C infection or to be HIV positive
Use of any nitrosourea or mitomycin-C
Has received any thrombocytopenic growth factor
Has received a marrow or peripheral blood stem cell infusion
Known hypersensitivity to any recombinant E. coli-derived product
